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Abstract
Objective: To assess the feasibility of measuring short-term effects of inhaled recombinant human deoxyribonuclease (rhDNase,
Pulmozyme ) on lung function, pulse oximetry and symptom scores in infants and toddlers with stable cystic fibrosis. Design:
open-label randomized placebo controlled cross-over pilot study. Patients and methods: We treated nine CF patients (0.7–1.9
years) with nebulised rhDNase (2.5 mg) and NaCl 0.9% (10 ml) via jet nebulizer cross-over once daily during 2-week treatment
blocks. Measurements were performed at baseline and after treatment blocks and consisted of lung function tests (plethysmography
and tidal rapid thoraco-abdominal compression technique), overnight pulse oximetry, and daily symptom scores. Results: DNase
treatment and the different assessments were well tolerated by all children and their parents. Lung function showed increased
airway patency after treatment with rhDNase (P-0.001), but not after NaCl 0.9%. Overnight pulse oximetry and daily symptom
scores did not change during the study period. Conclusions: This pilot study indicates that objective assessment of the effects of
rhDNase is feasible in infants with CF who have little or no respiratory symptoms. Our results warrant a larger randomized
placebo-controlled trial.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Viscous bronchial secretions are an important factor
in the pathogenesis of CF lung disease, resulting in
chronic occlusion of airways, and eventually leading to
fatal respiratory failure in over 90% of the patients w1x.
The abnormal viscosity of CF mucus is partly due to
the large amount of high molecular weight DNA, which
is released from disintegrating neutrophils. In CF spu-
tum, concentrations of 3–14 mg DNAyml are present
w2x. Recombinant human DNase has been shown to
reduce CF sputum viscosity in vitro and improve sputum
clearance w3,4x. Inhaled rhDNase is safe, improves
pulmonary function, reduces the frequency of respiratory
tract infections requiring parental antibiotics and
improves well-being in CF patients over 5 years of age
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w5–9x. Beneficial effects have been shown in older
patients after short-term (10 days) and long-term (6
months) administration w5,8,10x and a recent study in
children 6–10 years of age with normal lung function
demonstrates that long-term rhDNase treatment results
in a reduction of exacerbation frequency, and a sustained
improvement of lung function compared to placebo w9x.
Whether rhDNase improves lung function in young
children has not been systematically investigated. The
lungs of infants with CF appear to be histologically
normal at birth w11x, but initial stages of CF lung
pathology already occur within weeks to months after
birth and give rise to mucus plugging of bronchioles,
colonization with microorganisms, gas trapping and
reduced flow rates w12–14x. Furthermore, CF infants
without symptomatic lung disease may have significant
endobronchial bacterial infections associated with
inflammation, influx of neutrophils and increased DNA
levels w13,15,16x, and structural abnormalities can be
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observed on high resolution CT scans in many young
children with CF w17,18x. These observations indicate
that CF lung disease starts early in infancy and provide
a rationale for early treatment to improve lung function
and to prevent or reduce structural damage of lung
tissue. The aim of this study was to examine the
feasibility and sensitivity of various clinical endpoints
to asess effects of inhaled rhDNase in stable CF infants.
2. Methods
2.1. Study population
CF patients 0–2 years of age were recruited from the
outpatient clinic of the CF center of Sophia Children’s
Hospital. Inclusion criteria were: CF diagnosed by a
positive sweat test andyor two mutations in the CFTR
gene together with at least one clinical manifestation,
and a stable pulmonary condition during the previous
month. Exclusion criteria were: need for systemic cor-
ticosteroids, allergic bronchopulmonary aspergillosis,
intensive care treatment, previous treatment with rh-
DNase, surgical procedures during the trial, infection
with Burkholderia Cepacia and inability to comply with
the protocol. The local ethics committee approved the
protocol and written parental consent was obtained.
2.2. Study design
This open-label controlled pilot study had a cross-
over design with 2–3 weeks treatment blocks (ABBy
BAA design). Patients were randomly assigned to one
of the following two treatment regimens. Active treat-
ment consisted of once daily 2.5 mg nebulized rhDNase.
Placebo treatment consisted of nebulization of 10 ml
NaCl 0.9% once daily. The latter was chosen since at
the time of the study it was not possible to obtain
identical ampoules containing placebo or rhDNase. For
this reason active treatment was compared to daily
nebulisation of 10 ml NaCl 0.9% which was considered
standard treatment in our hospital at the time of the
study. DNase and NaCl 0.9% were delivered using a
Porta-Neb compressor and a Sidestream nebulizer via a
face mask (Medic Aid, West Sussex, UK). All patients
first entered a 4 weeks run-in phase in which 10 ml of
NaCl 0.9% was nebulised once daily. At the start of the
run-in period, the parents received practical and written
instruction on handling and application of the nebulizer.
During the run-in phase the parents were trained how
to do the symptom scoring and how to use the pulse
oximetry. Routine treatment was maintained throughout
the study. None of the patients used ‘classic mucolytics’,
daily bronchodilators, or prophylactic antibiotic treat-
ment. After the visit at the start of the run in period the
patients were seen four more times: at the end of the
run-in phase and subsequently after each of the 2–3
weeks treatment blocks.
2.3. Methods
During the total study period the parents were asked
to record symptoms on a diary card for the following
items (0sno symptoms; 2ssevere symptoms), includ-
ing coughing during the day and at night, expectoration
of sputum, dyspnea at rest and during exercise, wheez-
ing, level of activity and appetite. Parents were asked
to count breathing frequency during quiet sleep every
evening, and to note special events like change in
medication, periods of fever, or interfering illnesses. The
following assessments were performed every 2 weeks:
1. Physical examination with special attention to
breathing frequency, lung sounds, retractions and
nasal flaring.
2. Lung function tests consisted of measurements of
maximal flow at FRC (V9max ) as a measure ofFRC
airway patency, using the tidal rapid thoracic com-
pression technique (TRTC) w19,20x, and of Functional
Residual Capacity using plethysmography (FRCp),
measured using an infant plethysmograph (modified
‘Baby-Body’, Jaeger, Wurzburg, Germany) using a¨
face mask and shutter attached to a pneumotacho-
graph. FRCp was related to reference equations and
expressed as Z-scores w20x. Partial flow–volume
curves were obtained with the TRTC using an inflat-
able jacket according to published guidelines w20x.
Jacket inflation was repeatedly triggered at end-
inspiration with increasing pressures until flow-limi-
tation. Prior to the measurements children were
sedated (oral chloralhydrate 75 mgykg). The maxi-
mal, median and mean values of 3 to 5 recordings of
V9max were used in the analyses, to compare theFRC
sensitivity of each mode of expressing airway patency.
These values were expressed as raw data or as Z-
scores relative to reference equations w20x. Up to four
measurement sessions were conducted, with 2 week-
intervals. Baseline measurement was defined as the
lung function measurement after the run-in period.
3. Overnight measurements of oxygen saturation, heart
rate and breathing frequency by means of pulse
oximetry and thoracic impedance were carried out at
home during the last night of each treatment period
using a pulse oximeter (Edentrace II plus model
3711; EdenTec , Eden Prairie, USA). Acoustic alarm
signals were silenced to minimize interference with
sleep. Mean SaO , desaturation index, average heart2
rate and average breathing frequency were calculated
from at least 8 h of sleep recording. Desaturations
were defined as episodes with drops in SaO from2
baseline (-96%) of at least 4% during longer than
10 s. In normal infants, the number of such desatur-
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Table 1
Baseline characteristics of nine CF patients (means"S.E.M.)
Group I Group II
DNase treatment first NaCl treatment first
Patients (n) 5 4
Age (years) 1.28"0.17 1.53"0.15
Sex MyF 4y1 3y1
Height (cm) 79"3 81"2
Weight (kg) 10.2"0.7 10.4"0.6
Baseline after run-in:
Symptom-score 5.1"1.6 3.1"1.3
V9max (ml s )y1FRC 207"72 233"56
FRCp (ml kg )y1 32.2"6.0 31.0"5.5
Overnight oxygen saturation (%) 95.0"1.6 95.3"1.7
Table 2
Assessments of symptoms and home registrations during treatment in nine patients (mean"S.D.)
Run-in 4 weeks NaCl 2 weeks DNase 2 weeks
Cumulative symptom score 4.0"0.8 3.1"1.0 2.9"1.2
Overnight oxygen saturation (%) 95.0"0.5 95.8"0.7 96.0"0.7
Desaturation index 2.9"1.2 1.0"0.5 1.6"0.5
Time spent between 90 and 95% saturation (%) 37.4"12.5 27.8"10.3 25.9"10.1
Mean breathing frequency (min )y1 32"3 28"2 27"2
Heart frequency (beats min )y1 106"4 108"5 111"3
ations is 1.4–3 per h w21,22x. The desaturation index
was defined as the number of desaturations divided
by the recording time in hours. The breathing fre-
quency was calculated as an average from undisturbed
impedance signals counted during 1 min in the
beginning, 1 min in the middle and 1 min at the end
of a recording. In case of technical failure or too
short recording time the recording was repeated one
night later. The data were processed with ETS 2.5
software (Infiniti Medical, Taby, Sweden) and visu-¨
ally checked afterwards.
2.4. Data analysis
Endpoints after the treatment blocks were compared
with baseline using paired t-tests after verifying that
data were normally distributed. When lung function
after 4 weeks of treatment was missing, and not after 2
weeks of treatment, the values after 2 weeks were
analyzed. Tests of significance were two-sided and
significance assumed at 5% level of probability.
3. Results
Nine infants were included and completed the study
(Table 1). During the study three patients received a
course of oral antibiotics because of worsening of
symptoms: two during saline treatment and one during
rhDNase treatment, with recovery in 2–3 weeks.
3.1. Symptoms
Mean daily symptom scores were similar in both
treatment groups (Table 2). However, the scores of the
subitems dyspnea, wheezing and level of activity were
mostly near zero during the run-in period, which implied
no room for improvement. None of the children had
positive sputum cultures for pseudomonas.
3.2. Physical examination
Physical examination after 2 weeks of NaCl 0.9%
revealed retractions in four patients and wheezing
sounds in three patients. After 2 weeks of rhDNase
treatment retractions were seen in five patients and
wheezes heard in three. Mean daily breathing frequen-
cies were similar for treatment with saline or rhDNase.
3.3. Lung function
Not all measurements were successful because some
children did not sleep (two occasions) or awoke too
early (eight occasions). One patient was excluded for
further analysis since baseline lung function could not
be obtained. Mean (S.D.) baseline V9max Z-scoreFRC
was y1.7 (1.3) w20x, with subnormal values in 4 out
of 8 infants. After 2 weeks of treatment with rhDNase
successful measurements were obtained in six patients,
and a mean (95% CI) increase of V9max wasFRC
observed of 66 (41–90) mlys (Ps0.001) compared to
baseline. After 2 weeks of NaCl treatment successful
186 M.t. Berge et al. / Journal of Cystic Fibrosis 2 (2003) 183–188
Fig. 1. Changes of V9max compared to baseline following treat-FRC
ment with RhDNase (8 paired measurements, left panel) or NaCl
0.9% (6 paired measurements, right panel). Treatment periods: 4
weeks, (open circles), or 2 weeks (open squares); *: P-0.002, paired
t-test. (RhDNase compared to saline), left panel.
Fig. 2. Individual values of V9max during the study for group 1FRC
(upper panel) and group 2 (lower panel).
measurements were obtained in seven patients, with no
significant change of V9max compared to baselineFRC
(mean (95% CI): 35 (y26, 95) mlys). When all
available data were combined, an increase of V9maxFRC
was observed after rhDNase treatment in 8 out of 8
infants (mean (95% CI) increase: 72 (38–107) mlys)
after 2 or 4 weeks rhDNase treatment (Ps0.002),
whereas no significant difference was found after treat-
ment during 2 or 4 weeks with NaCl 0.9%, compared
with baseline (Fig. 1). In the four infants who started
with 2 weeks of rhDNase, an initial improvement of
V9max during rhDNase treatment was followed by aFRC
decline during 4 weeks of NaCl treatment (Fig. 2). The
mean values of FRCp (mlykg) were in the high-normal
range at all time points. Two patients showed patholog-
ically high values of FRCp that did not change appre-
ciably after 2 weeks of rhDNase treatment. Mean (S.D.)
baseline FRCp was 32(12) mlykg and remained similar
during treatment with rhDNase or saline (33(10) and
31(9) mlykg, respectively).
3.4. Overnight oximetry
Measurements were well accepted. Mean desaturation
index and mean breathing frequency showed a trend
towards improvement after treatment with rhDNase for
2 weeks, but the percentage of total sleep time (TST)
with saturations above 95% tended to improve similarly
for both treatments (Table 2).
4. Discussion
In this pilot study we treated infants with stable CF
with inhaled rhDNase, and asessed the feasibility of
measuring overnight oxygen saturation and infant lung
function. At inclusion, all infants had normal or near-
normal lung function. Our findings show that objective
endpoints are feasible for the assessment of rhDNase
effects in CF infants, and suggest that rhDNase treatment
might improve airway patency. Clearly, this short-term
pilot study cannot predict whether long-term treatment
with rhDNase is of clinical benefit in infants with CF.
However, based on our results we feel such a study is
warranted for a number of reasons. Firstly, a substantial
improvement of lung function after rhDNase was
observed in all children. Compared to the reference
population the mean increase of V9max was 0.7 S.D.FRC
This 0.7 S.D. matches a 8% rise in peripheral flows like
the forced expiratory flow between 25% and 75% of
vital capacity (MEF25-75) that was observed in a large
rhDNase study in children with CF between 6 and 10
years of age with a relatively normal lung function w9x.
Like MEF25-75, V9max is likely to reflect the moreFRC
peripheral compartment of the lungs, which is affected
early in the course of CF lung disease w18x. We might
even underestimate the response to rhDNase in our
study in the unlikely event of a carry-over effect lasting
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longer than 4 weeks for those patients who started the
study on rhDNase treatment, or in the case that NaCl
0.9% contributes in a positive way to the clearance of
sputum in CF. False improvements in forced flow might
result from changes in baseline FRC. However, this
seems unlikely as no differences in FRCp were detected
by plethysmography at the same time. Our study con-
firms that repeated lung function testing is suitable and
feasible to assess the efficacy of various treatments in
infants with CF w23–26x. Secondly, overnight pulse
oximetry showed a trend of improvement in oxygenation
after treatment with rhDNase or NaCl. Although the
patients in our study were young and had early lung
disease and normal SaO while awake, they showed2
saturations below 95% during one-quarter of sleep time,
which suggests that already at this early stage ventila-
tion–perfusion mismatch exists. We observed improve-
ments in overnight pulse oximetry both after NaCl and
rhDNase treatment. This may be explained by increased
compliance with treatment regimens due to participation
in the study. We found no effects of rhDNase on the
number of desaturation episodes. The mean desaturation
index after the run-in period in our study population
was within normal limits after the run in period, leaving
little room for improvement.
Thirdly, a number of recent studies showed that
airway inflammation and lung function abnormalities
are present early in life w13,15,16x. Airway inflammation
in CF results in an increase in DNA content in sputum
w2x. Furthermore, it was shown with high resolution CT
that even in young children substantial irreversible
structural damage can be observed early in life w17,18x.
Since inflammation is present early in life in most young
children with CF it is likely that the DNA content in
the airways of our study population is elevated. Hence,
a beneficial effect of rhDNase in infancy seems plaus-
ible. Furthermore, our findings support the findings of
a recent study showing a positive effect of rhDNase on
high resolution CT scans and chest radiographs in
children in the same age range.
Thus, we feel that our observations warrant a study
in a larger population. Therapy with rhDNase appears
to be safe in older patients; only minor side effects were
observed in a long term large study in children of 6
years of age or older w9x. No side effects of rhDNase
treatment were observed in the present study and meas-
urements were well accepted by patients and parents. A
clear limitation of our study is that it only studied the
efficacy of 2 weeks of rhDNase treatment. However, in
previous studies the maximal response was obtained
within the first 2 weeks. Clearly a large scale efficacy
study of rhDNase in infants should be of longer duration
and include both functional measurements and structural
measurements, including overnight pulse oxymetry,
infant lung function testing, and, perhaps, high resolution
CT scanning (HRCT) w27x. HRCT may be more sensi-
tive than lung function testing to detect structural chang-
es w18x. Daily symptom scores and physical examination
seem insensitive endpoints. Exacerbation rates, as an
endpoint requires large numbers of patients w9x.
In conclusion, infant lung function and overnight
pulse oximetry are feasible endpoints to document
effects of rhDNase treatment of CF infants, and seemed
more sensitive than physical examination or symptom
scores. A double-blind placebo-controlled trial of rh-
DNase in CF infants, employing infant lung function
and overnight pulse oximetry as objective endpoints, is
now feasible and warranted.
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